This phase 3 trial compared investigative oral PCSK9 inhibitor enlicitide to placebo in patients with hypercholesterolemia who either had or were at risk for ASCVD, highlighting enlicitide’s superior efficacy in reducing LDL cholesterol. In…
This phase 3 trial compared investigative oral PCSK9 inhibitor enlicitide to placebo in patients with hypercholesterolemia who either had or were at risk for ASCVD, highlighting enlicitide’s superior efficacy in reducing LDL cholesterol. In…